With the health care sector remaining mostly flat several weeks into 2026, one of last year's success stories has turned into an investor nightmare as shares of Hims & Hers Health NYSE: HIMS continue to plummet from their record highs.

Retail investors talked up five hot stocks this week on X and Reddit, driven by hype, earnings, AI, and news flow.

HIMS is accelerating AI-driven preventive care with new menopause, low testosterone and multi-cancer testing, deepening its personalized digital health platform.

Hims & Hers Health ( NYSE:HIMS ) just made a bold move to take its personalized wellness platform global.

Guru Stock PicksLi Lu has made the following transactions:Sold out in SOCNew position in CROXStock News Stocks slip, private credit hit, oil climbs: Blue Owl Ca

Eucalyptus will add $450 million in annual revenue growing at a triple digit rate to Hims & Hers. The risk is in using the $1 billion in cash on the balance sheet to buy more growth.

Hims & Hers (NYSE:HIMS) announced on Thursday that it has entered a definitive agreement to acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion. The acquisition is expected to strengthen Hims & Hers' international presence and expand its personalized healthcare offerings.

HIMS fourth-quarter 2025 results are likely to benefit from new specialties and global expansion, but higher costs and GLP-1 scrutiny could cloud earnings.

88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ) has been flagged by Cavendish as sitting on a roughly 500mmboe opportunity at its South Prudhoe...

Hims and Hers Health (HIMS) announced it will acquire Australia-based digital healthcare company Eucalyptus in a deal valued at up to $1.15 billion, subject to cu